Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-02 in Advanced Solid Tumors
NCT07260591Phase 1Recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VSV-02 in solid tumor (advanced stage), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoints: Objective Response Rate at 24 months, Disease Control Rate at 24 months and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
VSV-02
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07260591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260591.